Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: EveryDose Mobile Application.
- Who it may be relevant to
- Registry conditions: Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Qualitative Study: Utilization of an Adherence Application
Overview
The purpose of this study is to learn about the experiences of cancer patients during treatment utilizing a mobile app called EveryDose© to track prescribed oral treatment for cancer. Based on these experiences, the study team will decide on expanding this pilot study to evaluate other methods that may prove to be beneficial in supporting cancer patient's ability to take cancer medications as prescribed (another common phrase used for this is adherence to treatment).
Interventions
- Behavioral EveryDose Mobile Application
Participants will use this application every day for up to 10 minutes, for up to 12 weeks. The purpose of the application is to improve medication adherence. Participants will receive an alert to the mobile device while at home to ensure medication was taken, and to serve as a medication log.
Primary outcome measures
- Percentage of patients who agree to use the EveryDose application [Time frame: up to 12 weeks]
- EveryDose application adherence measured by percentage [Time frame: up to 12 weeks]
- Medication Adherence measured by dose ratio [Time frame: up to 12 weeks]
Secondary outcome measures (1)
- Percentage of patient satisfaction measured by SUS [Time frame: 12 weeks (post intervention)]
Eligibility criteria
Inclusion criteria
- Any sex/gender Able to provide written informed consent
- Able to read/understand English or Spanish
- Diagnosis of hematologic or solid tumor cancer diagnosis
- Prescribed an oral anti-cancer drug as monotherapy treatment for the first time by their treating oncologist.
- Internet access on a smartphone, tablet, or computer
Exclusion criteria
- Less than 18 years of age
- Unable to provide written informed consent
- Unable to read/understand English or Spanish
- History of dementia or major psychiatric disease that would interfere with study participation
- Prior treatment with an oral anti-cancer treatment
- Participating in another clinical trial during the time of screening.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Supportive care
Study locations
United States · 1 center
- University of Miami — Miami
Identifiers
NCT: NCT06952790 · 20240618